0001104659-21-070514.txt : 20210521
0001104659-21-070514.hdr.sgml : 20210521
20210521163114
ACCESSION NUMBER: 0001104659-21-070514
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210520
FILED AS OF DATE: 20210521
DATE AS OF CHANGE: 20210521
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SQUINTO STEPHEN P
CENTRAL INDEX KEY: 0001231954
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39044
FILM NUMBER: 21949481
MAIL ADDRESS:
STREET 1: C/O ALEXION PHARMACEUTICALS INC
STREET 2: 352 KNOTTER DRIVE
CITY: CHESHIRE
STATE: CT
ZIP: 06410
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SpringWorks Therapeutics, Inc.
CENTRAL INDEX KEY: 0001773427
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 WASHINGTON BOULEVARD
CITY: STAMFORD
STATE: CT
ZIP: 06902
BUSINESS PHONE: 203-883-9490
MAIL ADDRESS:
STREET 1: 100 WASHINGTON BOULEVARD
CITY: STAMFORD
STATE: CT
ZIP: 06902
4
1
tm2117215-1_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2021-05-20
0
0001773427
SpringWorks Therapeutics, Inc.
SWTX
0001231954
SQUINTO STEPHEN P
C/O SPRINGWORKS THERAPEUTICS, INC.
100 WASHINGTON BLVD.
STAMFORD
CT
06902
1
0
1
0
Common Stock
2021-05-20
4
A
0
1106
0
A
126834
D
Common Stock
6186307
I
See footnote
Stock Option (Right to Buy)
75.94
2021-05-20
4
A
0
6998
0
A
2031-05-20
Common Stock
6998
6998
D
Represents restricted stock awards. The restricted stock awards shall vest in full on the earlier of (1) May 20, 2022 and (2) the next annual meeting of stockholders, subject to continued service to the Issuer on the vesting date.
Shares held by OrbiMed Private Investments VI, LP ("OrbiMed VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OrbiMed VI. OrbiMed Advisors, LLC ("Advisors") is the managing member of GP VI. By virtue of such relationship, GP VI and Advisors may be deemed to have voting and investment power with respect to the shares held by OrbiMed VI and as a result may be deemed to have beneficial ownership of such shares. The reporting person is an Executive Partner at Advisors. This report shall not be deemed an admission that the reporting person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
The options shall vest in full on the earlier of (1) May 20, 2022 and (2) the next annual meeting of stockholders, subject to continued service to the Issuer on the vesting date.
/s/ Francis I. Perier, Jr as Attorney-in-Fact
2021-05-21